1. Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer

   • Uri Galili

   Review 16 June 2004 Pages: 935 - 945

   

2. Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following “suicide” gene therapy in a murine colon carcinoma model

   • Abdul-Razzak Alsheikhly
   • Jehad Zweiri
   • Stephen E. Christmas

   Original Article 04 June 2004 Pages: 946 - 954

   

3. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization

   • E. Corsini
   • M. Gelati
   • A. Salmaggi

   Original Article 29 July 2004 Pages: 955 - 962

   

4. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

   • Joanna Galea-Lauri
   • James W. Wells
   • Farzin Farzaneh

   Original Article 14 May 2004 Pages: 963 - 977

   

5. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells

   • A. R. Dadabayev
   • M. H. Sandel
   • P. J. K. Kuppen

   Original Article 17 June 2004 Pages: 978 - 986

   

6. Anti-idiotype responses abrogate anti-CD4–induced tolerance to a tumor-specific antigen and promote systemic tumor immunity

   • Ronald C. Kennedy
   • Michael H. Shearer
   • Robert K. Bright

   Original Article 19 May 2004 Pages: 987 - 994

   

7. Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer

   • P. J. Russell
   • K. T. Ow
   • R. Martiniello-Wilks

   Original Article 28 July 2004 Pages: 995 - 1004

   

8. Virosomes as new carrier system for cancer vaccines

   • Ruth Schwaninger
   • Ernst Waelti
   • Claude D. Gimmi

   Original Article 05 June 2004 Pages: 1005 - 1017

   

9. Dendritic cells reduce number and function of CD4⁺CD25⁺ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma

   • Jan Schmidt
   • Sven Eisold
   • Angela Märten

   Original Article 05 June 2004 Pages: 1018 - 1026

   

10. Generation of human tumor-specific CTLs in HLA-A2.1–transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors

    • Angelos D. Gritzapis
    • Nectaria N. Sotiriadou
    • Constantin N. Baxevanis

    Original Article 26 May 2004 Pages: 1027 - 1040

    

11. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients

    • Silvio Buzzi
    • Diego Rubboli
    • Flavio Pironi

    Original Article 28 May 2004 Pages: 1041 - 1048

    

12. Lower percentages of monocytes with CD80, CD86 and HLA-DR molecule expression in pediatric cancer

    • Wlodzimierz Luczynski
    • Anna Stasiak-Barmuta
    • Maryna Krawczuk-Rybak

    Letter to the Editors 29 July 2004 Pages: 1049 - 1050

13. Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?

    • Selma Ugurel
    • Monika Lindemann
    • Hans Grosse-Wilde

    Letter to the Editors 30 June 2004 Pages: 1051 - 1051

14. Cancer gene therapy: new horizons in the East

    • Farzin Farzaneh
    • Nagy Habib
    • Peter Walden

    Meeting Report 03 July 2004 Pages: 1052 - 1053